Physician profile
Eugenio Rivera
NPI 1912029364
$7,249.94
in general payments reported to CMS, 2019-2025
19 companies · $1,535 in 2025
The $1,535 reported for 2025 was more than what 78% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,283 · 2020: $148 · 2021: $1,254 · 2022: $2,562 · 2023: $210 · 2024: $258 · 2025: $1,535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,056 · Travel and Lodging: $947.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,055.95 |
| Travel and Lodging | $946.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Treace Medical Concepts, INC. | $3,204.03 | 2021-2025 | |
| Paragon 28, INC. | $1,497.24 | 2022 | |
| Arthrosurface Incorporated | $1,066.73 | 2019 | |
| Horizon Therapeutics Plc | $235.16 | 2019-2022 | |
| Stryker Corporation | $187.05 | 2022-2025 | Prostep, Citrefix, Augment Injectable |
| Linvatec Corporation | $165.09 | 2025 | Neospan, Biobrace 23mm |
| Abbott Laboratories | $139.87 | 2023 | Proclaim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.97 | 2019-2021 | |
| Paratek Pharmaceuticals, INC. | $118.61 | 2024-2025 | Nuzyra |
| Abbvie INC. | $106.31 | 2022 | |
| Medtronic, INC. | $96.43 | 2024 | Venaseal |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $82.15 | 2019-2022 | |
| Smith+Nephew, INC. | $70.81 | 2020-2022 | |
| Pacira Pharmaceuticals Incorporated | $52.96 | 2025 | Exparel |
| Zimmer Biomet Holdings, INC. | $42.44 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zyla Life Sciences, INC. | $22.30 | 2019 | |
| Assertio Therapeutics, INC. | $18.48 | 2020 | |
| Bioventus LLC | $12.74 | 2019 | |
| Kerecis Limited | $7.57 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugenio Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.